Axsome’s Auvelity becomes first FDA-approved oral NMDA for major depressive disorder
The FDA has approved Axsome Therapeutics’ Auvelity for major depressive disorder (MDD) in adults, making it the first and only oral N-methyl D-aspartate (NMDA) receptor antagonist approved for this indication.